In last trading session, Lucid Diagnostics Inc (NASDAQ:LUCD) saw 1.01 million shares changing hands with its beta currently measuring 1.34. Company’s recent per share price level of $1.28 trading at -$0.04 or -3.03% at ring of the bell on the day assigns it a market valuation of $107.05M. That closing price of LUCD’s stock is at a discount of -27.34% from its 52-week high price of $1.63 and is indicating a premium of 50.78% from its 52-week low price of $0.63. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.76 million shares which gives us an average trading volume of 537.22K if we extend that period to 3-months.

For Lucid Diagnostics Inc (LUCD), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.

Lucid Diagnostics Inc (NASDAQ:LUCD) trade information

Upright in the red during last session for losing -3.03%, in the last five days LUCD remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $1.28 price level, adding 9.22% to its value on the day. Lucid Diagnostics Inc’s shares saw a change of 56.35% in year-to-date performance and have moved -7.91% in past 5-day. Lucid Diagnostics Inc (NASDAQ:LUCD) showed a performance of 0.00% in past 30-days. Number of shares sold short was 1.79 million shares which calculate 2.44 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 48.8% to its current value. Analysts have been projecting 2.5 as a low price target for the stock while placing it at a high target of 2.5. It follows that stock’s current price would drop -95.31% in reaching the projected high whereas dropping to the targeted low would mean a loss of -95.31% for stock’s current value.

Lucid Diagnostics Inc (LUCD) estimates and forecasts

This year revenue growth is estimated to rise 88.04% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.42M for the same. And 5 analysts are in estimates of company making revenue of 1.61M in the next quarter. Company posted 1.04M and 1M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -110.66% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 84.26% while estimates for its earnings growth in next 5 years are of 58.74%.

Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders

Insiders are in possession of 45.27% of company’s total shares while institution are holding 5.39 percent of that, with stock having share float percentage of 9.86%. Investors also watch the number of corporate investors in a company very closely, which is 5.39% institutions for Lucid Diagnostics Inc that are currently holding shares of the company. LUMINUS MANAGEMENT LLC is the top institutional holder at LUCD for having 0.73 million shares of worth $0.6 million. And as of 2024-06-30, it was holding 1.6124 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2461 of outstanding shares, having a total worth of $0.46 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 366.92 shares of worth $0.47 million or 0.62% of the total outstanding shares. The later fund manager was in possession of 193.99 shares on Dec 31, 2024 , making its stake of worth around $0.25 million in the company or a holder of 0.33% of company’s stock.